Consistently, and particularly relevant from the therapeutic point of view, the combined treatment with statins and the bispecific antibody scDb-hERG1-β1- which harnesses the hERG1/β1 integrin complex has a strong antineoplastic effect in an orthotopic preclinical mouse model of PDAC, decreasing tumor volume and proliferative activity and strongly improving mice survival, compared to treatment involving chemotherapeutic drugs like Gemcitabine [47]. The gene discussed is KCNH2; the disease is neoplasm.